Lung Therapeutics is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. The Company is currently developing a drug technology, LTI-03, for the treatment of Idiopathic Pulmonary Fibrosis. Preclinical evidence suggests that LTI-03 sustains survival of damaged lung cells throughout this novel mechanism of action, in addition to slowing and resolving the downstream progress of fibrosis.

HQAustin, US
Size (employees)11 (est)-21%
Lung Therapeutics was founded in 2013 and is headquartered in Austin, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Lung Therapeutics Office Locations

Lung Therapeutics has an office in Austin
Show all (1)
Report incorrect company information

Lung Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Lung Therapeutics total Funding

$17.9 m

Lung Therapeutics latest funding size

$14.30 m

Time since last funding

a year ago

Lung Therapeutics investors

Lung Therapeutics's latest funding round in June 2017 was reported to be $14.3 m. In total, Lung Therapeutics has raised $17.9 m
Show all financial metrics
Report incorrect company information

Lung Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Lung Therapeutics Company Life and Culture

Report incorrect company information